BioTuesdays

Tag - Joseph Schwartz

Selecta Biosciences

SVB starts Selecta Biosciences at OP; PT $7

SVB Securities initiated coverage of Selecta Biosciences (NASDAQ:SELB) with an “outperform” rating and $7 price target. The stock closed at 88 cents on June 3. Selecta is a clinical-stage biotech company advancing its...

PepGen

SVB Securities starts PepGen at OP; PT $40

SVB Securities launched coverage of PepGen (NASDAQ:PEPG) with an “outperform” rating and $40 price target. The stock closed at $10.88 on May 27. PepGen is a clinical-stage biotech advancing its enhanced delivery...

AN2 Theraputics

SVB Leerink starts AN2 Therapeutics at OP; PT $27

SVB Leerink launched coverage of AN2 Therapeutics (NASDAQ:ANTX) with an “outperform” rating and price target of $27. The stock closed at $14.79 on April 18.   AN2 is a clinical-stage biotech company developing therapies...

Pharvaris-Logo

SVB Leerink starts Pharvaris at OP; PT $50

SVB Leerink initiated coverage of Pharvaris B.V. (NASDAQ:PHVS) with an “outperform” rating and $50 price target. The stock closed at $39.23 on March 1. Pharvaris is developing therapies for rare diseases, with a focus...

inflaRx

SVB Leerink ups Inflarx to OP; PT to $10 from $7

SVB Leerink upgraded Inflarx (NASDAQ:IFRX) to “outperform” from “market perform” and raised its price target to $10 from $7, citing a “significant disconnect between the promise of IFX-1 in multiple applications, most...

Spruce-Biosciences-Logo

SVB Leerink starts Spruce Biosciences at OP; PT $35

SVB Leerink launched coverage of Spruce Biosciences (NASDAQ:SPRB) with an “outperform” rating and $35 price target. The stock closed at $20.30 on Nov. 2 Spruce is a late-stage biotech company developing therapies for...